-+ 0.00%
-+ 0.00%
-+ 0.00%

BioLineRx Agrees To Sell Its Rights To Certain Future Royalty Payments From APHEXDA To Soleus Capital Management And Its Affiliates For One-Time Payment Of $5.6M

Benzinga·11/18/2026 12:04:04
Diffusion vocale

- Transaction provides non-dilutive capital through sale of BioLineRx's portion of future APHEXDA royalties -

- Funds to support clinical development of GLIX1, including ongoing Phase 1/2a clinical trial, which is currently enrolling the fourth of five planned dosing cohorts -

- BioLineRx retains rights to future commercial milestone payments under its existing license agreement with Ayrmid -

TEL AVIV, Israel, Nov. 18, 2026 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ:BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced that it has entered into an agreement for the sale of its rights to certain future royalty payments from APHEXDA® (motixafortide) to Soleus Capital Management, L.P. and its affiliates ("Soleus") for a one-time payment of $5.6 million.